Twist Bioscience (TWST) COO Finn Patrick John Sells Shares, Exercises Options

What Happened
Finn Patrick John, President and Chief Operating Officer of Twist Bioscience (TWST), exercised options to acquire 23,355 shares at $67.85 each (cost ≈ $1,584,637) and executed multiple open‑market sales of a total ~78,355 shares on August 18, 2026 for aggregate proceeds of ≈ $9.22 million. The exercise and the stock sales occurred the same day; the filing includes a derivative entry reporting 23,355 shares disposed at $0.00 (recorded as a derivative disposition).

Key Details

• Transaction date: August 18, 2026. Form 4 filed August 20, 2026.
• Option exercise: 23,355 shares acquired @ $67.85 (total ≈ $1,584,637). Option was 100% exercisable as of Dec 19, 2022 (see footnote F9).
• Open‑market sales (total ≈ 78,355 shares) executed in multiple tranches at prices ranging roughly from $115.35 to $122.82 per share, producing total proceeds ≈ $9,217,606. (Footnotes F2–F8 list weighted averages and the price ranges for each tranche.)
• Footnote F1: Transactions were made pursuant to a Rule 10b5‑1 trading plan adopted May 18, 2026.
• Shares owned after the transactions: not disclosed in the provided excerpt of the filing. Consult the full Form 4 for total holdings.
• Filing timeliness: Form 4 filed two days after the reported transactions (appears timely).

Context

• This filing shows an option exercise followed by same‑day secondary sales. That pattern is commonly used to cover exercise costs or diversify holdings; the filing itself does not state the insider’s motivations.
• Because the trades were made under a 10b5‑1 plan (per F1), they were pre‑arranged trading instructions rather than ad‑hoc market timing.
• For full detail (exact per‑price breakdowns, total post‑transaction holdings, or the nature of the $0.00 derivative disposition), review the complete Form 4 available from the SEC (Accession No. 0001214659-26-010645).